Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Rnaimmune
AddedFeb 17, 2024
UpdatedJun 18, 2026
Rnaimmune

Rnaimmune

Series A

RNAimmune: A biotech startup with 20+ years expertise in optimizing mRNA technology for medicine.

HQ
Gaithersburg, MD, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

RNAimmune, a biotechnology startup, was founded with over 20 years of expertise in messenger RNA (mRNA) technology. The company's core mission is to leverage mRNA as a data carrier to instruct the human body to produce its own therapeutic proteins. RNAimmune focuses on developing innovative medical solutions for oncology, immunology, infectious diseases, and vaccines. Their vision is to treat, cure, and prevent some of the most devastating and complex diseases by pursuing the most promising scientific advancements.

Notable affiliated people and investors include leading experts in biotechnology and seasoned investors in the healthcare sector. RNAimmune has achieved significant milestones in optimizing mRNA technology for medical purposes, contributing to the development of novel treatments and vaccines. The company's impact is reflected in its commitment to addressing unmet medical needs and improving patient outcomes through cutting-edge mRNA-based therapies.

Rnaimmune - Similar Companies

Moderna logo

Moderna

modernatx.com

Innovac Therapeutics logo

Innovac Therapeutics

innovactx.com

Sensible Biotechnologies logo

Sensible Biotechnologies

sensible.bio

VaxEquity logo

VaxEquity

HDT Bio logo

HDT Bio

hdt.bio

NeuImmune logo

NeuImmune

neuimmune.com

Rnav8 Bio logo

Rnav8 Bio

Inimmune logo

Inimmune

inimmune.com

Airna logo

Airna

airna.com

ReviR Therapeutics logo

ReviR Therapeutics

revirtx.com

Nano RED logo

Nano RED

Chimeron Bio logo

Chimeron Bio

ReNAgade Therapeutics logo

ReNAgade Therapeutics

Replicate Bioscience logo

Replicate Bioscience

Cisterna Biologics logo

Cisterna Biologics

cisternabx.com

Rnaimmune - Quick Facts

Who are Rnaimmune's competitors?

Companies similar to Rnaimmune include Moderna, Innovac Therapeutics, Sensible Biotechnologies and VaxEquity.

When was Rnaimmune founded?

Rnaimmune was founded in 2020.

Where is Rnaimmune's headquarters located?

Rnaimmune's headquarters is located in Gaithersburg, MD, US.

When was Rnaimmune's last funding round?

Rnaimmune's most recent funding round was for $27M (USD) in March 2022.

How much has Rnaimmune raised to-date?

As of Mar 29, 2022, Rnaimmune has raised a total of $39.4M (USD).

How many employees does Rnaimmune have?

Rnaimmune has 16 employees as of Feb 4, 2024.

Rnaimmune - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
  • mRNA
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Therapeutics
  • Vaccines
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software